Stock Analysts’ Upgrades for June 1st (APLT, ARHS, ASTS, ATHX, ATNM, ATTO, AURA, AVDX, BAK, BBLN)

Stock Analysts’ upgrades for Wednesday, June 1st:

Applied Therapeutics (NASDAQ:APLT) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $1.50 target price on the stock. According to Zacks, “Applied Therapeutics Inc. is a clinical-stage biopharmaceutical company. It engages in developing drug candidates for unmet medical need. The company’s product candidate consists of AT-001, for the treatment of Diabetic Cardiomyopathy; AT-007, for the treatment of Galactosemia and AT-003, for the treatment of diabetic retinopathy which are in clinical stage. Applied Therapeutics Inc. is based in New York, United States. “

Arhaus (NASDAQ:ARHS) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $6.50 target price on the stock. According to Zacks, “Arhaus Inc. is a lifestyle brand and omni-channel retailer of premium home furnishings. The company offers assortment of heirloom quality products. Arhaus Inc. is based in BOSTON HEIGHTS, Ohio. “

AST SpaceMobile (NASDAQ:ASTS) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “AST SpaceMobile is building space-based cellular broadband network to operate directly with standard, unmodified mobile devices based on its extensive IP and patent portfolio. AST SpaceMobile, formerly known as New Providence Acquisition Corp., is based in Texas, United States. “

Athersys (NASDAQ:ATHX) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Athersys, Inc., a late stage biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused primarily on treating critical care indications neurological conditions, cardiovascular diseases, inflammatory and immune disorders, pulmonary and other conditions. The company’s lead platform product is MultiStem cell therapy, an off the shelf allogeneic stem cell product currently in Phase 3 clinical development for treating ischemic stroke. Based on promising Phase 2 results, this program has received Fast Track and RMAT (equivalent to Breakthrough Therapy for regenerative medicine treatments) designations from the FDA, as well as similar designations in Japan. The company also has an ongoing Phase II clinical study for treating patients with acute myocardial infarction; a planned Phase II for trauma (supported by the DOD). “

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $6.25 target price on the stock. According to Zacks, “Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium’s lead application for their ARCs is targeted conditioning, which is intended to selectively deplete a patient’s disease or cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, Gene Therapy or Adoptive Cell Therapy (ACT) such as CAR-T to enable engraftment of these transplanted cells with minimal toxicities. With their ARC approach, they seek to improve patient outcomes and access to these potentially curative treatments by eliminating or reducing the non-targeted chemotherapy that is used for conditioning in standard practice currently. Their lead product candidate, I-131 apamistamab (Iomab-B) is being studied in the ongoing pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. The SI “

Atento (NYSE:ATTO) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Atento S.A. is a provider of customer relationship management and business process outsourcing (CRM BPO) services in Latin America and Spain. Its CRM BPO services include customer service, sales, credit management, technical support, back office, and service desk, as well as other BPO process services, such as training activities, workstation infrastructure, interactive voice response port implementation, telecommunications infrastructure, application development, and others. The Company’s clients are mostly multinational corporations in sectors such as telecommunications, banking and finance, health, consumption and public administration, among others. Atento S.A. is based in Luxembourg. “

Aura Biosciences (NASDAQ:AURA) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $20.00 price target on the stock. According to Zacks, “Aura Biosciences Inc. is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates to target and destroy cancer cells selectively while activating the immune system. The company’s lead product candidate includes AU-011. Aura Biosciences Inc. is based in CAMBRIDGE, Mass. “

AvidXchange (NASDAQ:AVDX) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $9.75 target price on the stock. According to Zacks, “AvidXchange Holdings Inc. is a provider of accounts payable automation software and payment solutions for middle market businesses and suppliers. The company’s software-as-a-service-based, end-to-end software and payment platform digitizes and automates the AP workflows for businesses and supplier. AvidXchange Holdings Inc. is based in CHARLOTTE, N.C. “

Braskem (NYSE:BAK) was upgraded by analysts at Zacks Investment Research from a strong sell rating to a buy rating. Zacks Investment Research currently has $21.00 target price on the stock. According to Zacks, “Braskem SA figures as the largest petrochemical operation in Latin America and among the five largest private companies in Brazil. With industrial facilities located in Alagoas, Bahia, São Paulo and Rio Grande do Sul, Braskem produces primary base petrochemicals such as ethylene, propylene, benzene, caprolactam, DMT and termoplastic resins (polypropylene, polyethylene, PVC and PET) gas and GLP. “

Babylon (NYSE:BBLN) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Babylon Holdings Limited is a digital healthcare company. Babylon Holdings Limited, formerly known as Alkuri Global Acquisition Corp., is based in PALO ALTO, Calif. “

Build-A-Bear Workshop (NYSE:BBW) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $23.00 price target on the stock. According to Zacks, “Build-A-Bear Workshop is the leading and only national company providing a make your own stuffed animal interactive retail-entertainment experience. “

Want More Great Investing Ideas?

Receive News & Ratings for Applied Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.